UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Allogeneic natural killer cell therapy

Blood, 2023-02, Vol.141 (8), p.856-868

2023

Volltextzugriff (PDF)

Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma

Blood, 2017-01, Vol.129 (4), p.473-483

2017

Volltextzugriff (PDF)

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

Blood, 2020-11, Vol.136 (20), p.2308-2318

2020

Volltextzugriff (PDF)

Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

Blood, 2023-06, Vol.141 (26), p.3153-3165

2023

Volltextzugriff (PDF)

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Blood, 2022-03, Vol.139 (13), p.1999-2010

2022

Volltextzugriff (PDF)

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Blood, 2023-11, Vol.142 (Supplement 1), p.4813-4813

2023

Volltextzugriff (PDF)

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Blood, 2023-11, Vol.142 (Supplement 1), p.4834-4834

2023

Volltextzugriff (PDF)

Memory-Like Natural Killer Cells

Blood, 2018-11, Vol.132 (Supplement 1), p.SCI-8-SCI-8

2018

Volltextzugriff (PDF)

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Blood, 2023-11, Vol.142 (Supplement 1), p.466-466

2023

Volltextzugriff (PDF)

Mechanisms of Cytokine-Induced NK Cell Therapy: IL-12/15/18 Induce a Unique Transcriptional, Epigenetic, and Functional Human NK Cell Memory Program

Blood, 2023-11, Vol.142 (Supplement 1), p.2067-2067

2023

Volltextzugriff (PDF)

Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo

Blood, 2021-11, Vol.138 (Supplement 1), p.194-194

2021

Volltextzugriff (PDF)

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Blood, 2019-11, Vol.134 (Supplement_1), p.3237-3237

2019

Volltextzugriff (PDF)

Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT)

Blood, 2019-11, Vol.134 (Supplement_1), p.1954-1954

2019

Volltextzugriff (PDF)

Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Blood, 2019-11, Vol.134 (Supplement_1), p.3307-3307

2019

Volltextzugriff (PDF)

Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function

Blood, 2018-11, Vol.132 (Supplement 1), p.1271-1271

2018

Volltextzugriff (PDF)

Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors

Blood, 2019-11, Vol.134 (Supplement_1), p.869-869

2019

Volltextzugriff (PDF)

Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development

Blood, 2019-11, Vol.134 (Supplement_1), p.2464-2464

2019

Volltextzugriff (PDF)

Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML)

Blood, 2015-12, Vol.126 (23), p.101-101

2015

Volltextzugriff (PDF)

Human CD56bright NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming

Blood, 2016-12, Vol.128 (22), p.550-550

2016

Volltextzugriff (PDF)

Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing

Blood, 2015-12, Vol.126 (23), p.574-574

2015

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

Allogeneic natural killer cell therapy

Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma

CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Memory-Like Natural Killer Cells

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Mechanisms of Cytokine-Induced NK Cell Therapy: IL-12/15/18 Induce a Unique Transcriptional, Epigenetic, and Functional Human NK Cell Memory Program

Eomes and T-Bet Expression Are Required By Mature Primary Human NK Cells for Anti-Leukemia Responses In Vivo

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses

Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT)

Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function

Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors

Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development

Cytokine-Induced Memory-like NK Cells Have a Distinct Single Cell Transcriptional Profile and Persist for Months in Adult and Pediatric Leukemia Patients after Adoptive Transfer

Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML)

Human CD56bright NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming

Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing

Aktive Filter

Suchergebnisse filtern